A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
Latest Information Update: 20 May 2021
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Registrational; Therapeutic Use
- Sponsors Menlo Therapeutics; VYNE Therapeutics
- 06 Apr 2020 Primary endpoint has not been met. (Worst-Itch Numeric Rating Scale (WI-NRS) 4-point responder rate), according to a Menlo Therapeutics media release.
- 06 Apr 2020 Topline results published in the Menlo Therapeutics media release
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.